Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years
Tóm tắt
The role of human papillomavirus (HPV) antibodies acquired through natural infection and their role in protection for subsequent cervical or oral HPV-carriage remains unclear. A total of 267 women, with a 36-months follow-up, from the Finnish Family HPV (FFHPV) study were evaluated to shed more light on persistent HPV-specific antibodies to genital or oral HPV-carriage, clearance or persistence during the three years follow-up. The type-specific seroprevalence for HPV genotypes 6, 11, 16, 18 and 45 in these women was assessed in relation to the detection of the same genotype or any HPV in their oral and genital samples. The following HPV serological outcomes where detected: being always seronegative, seroconversion or persistent seropositivity.
Genital HPV16 infections were most prevalent at the end of the follow-up (24- and 36-month visit) among women who tested always seronegative for HPV16. No such associations between serology and HPV detection were established for the other HPV genotypes in the genital or oral samples. The development of long-term type-specific HPV 6,11,16,18 and 45 persistence (≥ 24 months) or clearance of the genital or oral infections was not different among the women with high HPV genotype specific antibody levels and those testing always HPV-seronegative. No significant role was disclosed for the acquired natural high-level- or persistent HPV antibodies as determinants of the genital or oral HPV infection outcomes in these young, non-vaccinated women.
Tài liệu tham khảo
Syrjänen S, Waterboer T, Sarkola M, et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol. 2009;90:1515–26. https://doi.org/10.1099/vir.0.007823-0.
Safaeian M, Castellsagué X, Hildesheim A, et al. Risk of HPV-16/18 infections and associated cervical abnormalities in women seropositive for naturally acquired antibodies: pooled analysis based on control arms of two large clinical trials. J Infect Dis. 2018;218:84–94. https://doi.org/10.1093/infdis/jiy112.
Beachler DC, Jenkins G, Safaeian M, et al. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213:1444–54. https://doi.org/10.1093/infdis/jiv753.
Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123–37.
Stanley M. HPV—immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19. https://doi.org/10.1186/1750-9378-5-19.
Syrjänen S. Oral manifestations of human papillomavirus infections. Eur J Oral Sci. 2018;126:49–66. https://doi.org/10.1111/eos.12538.
Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9. https://doi.org/10.1086/315498.
Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70. https://doi.org/10.1016/S0140-6736(07)60946-5.
Wilson L, Pawlita M, Castle PE, et al. Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis. 2014;210:448–55. https://doi.org/10.1093/infdis/jiu104.
Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res. 2013;6:1242–50. https://doi.org/10.1158/1940-6207.CAPR-13-0203.
Matthijsse SM, Van Rosmalen J, Hontelez JAC, et al. The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model. PLoS ONE. 2015;10:1–14. https://doi.org/10.1371/journal.pone.0116618.
Louvanto K, Rautava J, Willberg J, et al. Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: a six-year follow-up study. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0053413.
Paaso AE, Louvanto K, Syrjänen KJ, et al. Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol. 2011;92:2034–46. https://doi.org/10.1099/vir.0.032011-0.
Vuorinen S (2020) Natural acquired high-level HPV antibodies do not influence unvaccinated women’s genital or oral HPV infection outcomes. UTUPub, University of Turku, Finland (2020-04-03). https://urn.fi/URN:NBN:fi-fe2020042219974
Schmitt M, Bravo IG, Snijders PJF, et al. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44:504–12. https://doi.org/10.1128/JCM.44.2.504-512.2006.
Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem. 2005;51:1845–53. https://doi.org/10.1373/clinchem.2005.052381.
Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006;309:200–4. https://doi.org/10.1016/j.jim.2005.11.008.
Robbins HA, Li Y, Porras C, et al. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis. 2014. https://doi.org/10.1186/1471-2334-14-120.
Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 2008. https://doi.org/10.1371/journal.ppat.1000091.
Coseo S, Porras C, Hildesheim A, et al. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis. 2010;37:706–14. https://doi.org/10.1097/OLQ.0b013e3181e1a2c5.
Castellsagué X, Naud P, Chow SN, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: Analysis of the control arm of PATRICIA. J Infect Dis. 2014;210:517–34. https://doi.org/10.1093/infdis/jiu139.